Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01174524|
Recruitment Status : Completed
First Posted : August 3, 2010
Last Update Posted : August 3, 2010
|Condition or disease||Intervention/treatment||Phase|
|Quality of Life Menopause Contraception||Drug: gestoden 60 mcg Drug: ethinylestradiol 15 mcg||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||November 2008|
Experimental: gestoden and ethinylestradiol
Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.
The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients.
Drug: gestoden 60 mcg
gestoden 60 mcg, once a day, administered in 24/4 regimen.
Drug: ethinylestradiol 15 mcg
ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
- Quality of life [ Time Frame: eleven months ]
- Quality of life in differents phases of menacme [ Time Frame: eleven months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01174524
|Hospital Geral de Fortaleza|
|Fortaleza, Ceara, Brazil, 60115290|
|Principal Investigator:||joao MM Silva, PhD Student||Hospital Geral de Fortaleza|